Anti-BCMA CAR T-cell therapy is developed based on the concept that BCMA is preferentially expressed by plasma cells compared to other normal late-stage B cells, making it an ideal anti-tumor target in MM treatment (24). Here, TNFRSF17 is linked to Miyoshi myopathy.